share_log

Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Benzinga ·  May 11, 2023 04:47

Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment